← Back to Clinical Trials
Recruiting NCT06621823

NCT06621823 Image-guided Ultrasound Robotic Intraoperative Evaluation of Lymph-nodes Status in Gynecological Malignancies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06621823
Status Recruiting
Phase
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Condition Lymph Node Metastasis
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2024-07-25
Primary Completion 2025-12-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
image-guided surgery technique

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2024-07-25 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The assessment of lymph node status is of crucial importance in gynaecological malignancies. Indeed, the prognosis and adjuvant treatment regimens are strongly influenced by the presence of nodal involvement. Systematic extensive lymphadenectomies are often performed for staging, diagnosis of skip metastases and to define the radiation field when radiotherapy treatments are required. Nevertheless, these can lead to significant short-term and long-term lymphatic complications, which are difficult to justify if the lymph nodes are free from metastasis. To avoid unnecessary comprehensive procedures in early-stage cancers, evaluation of the sentinel lymph node has acquired a valuable role even if limitations are still present (rate of frozen section false negative, "empty packets" and mapping failure). The introduction of an intra-operative non-invasive imaging technique capable of describing the presence and characteristics of lymph nodes could help in (1) eliminating the risk of empty packet, (2) orienting the intraoperative decision while avoiding the drawbacks of frozen section (time and resources, partial destruction of the tissue material), (3) orientate the pathological section if frozen section is used. To date, technological advancements have paved the way for enhanced intra-operative assessment of cancerous organs and lesions. Over the past decade, the evolution of robotic surgery combined with advancements in image-guided surgery techniques has led to the introduction of ultrasound probes designed specifically for intraoperative ultrasound during robotic surgery (RIOUS). Apart from the conventional rigid laparoscopic probes, which can be inserted through an accessory trocar, there are robotic probes tailored to fit device arms, and drop-in flexible probes that are becoming increasingly relevant in the scientific panorama. Notably, the latter drop-in probes feature a rigid segment designed for compatibility with robotic graspers, leveraging the dexterity and rotational manoeuvrability inherent to robotic surgery. Such probes, already proven effective in evaluating liver and kidney lesions as well as tumour margins, hold promise for intraoperative lymph node assessments due to the possibility of reaching difficult anatomical spaces thanks to the robotic-assisted movements

Eligibility Criteria

Inclusion Criteria: * Women undergoing robotic surgery for gynecological malignancies (ovarian, endometrial, cervical cencers) * Need for nodal excision (staging or cytoreductive reasons) * 18-99 years old * Absence of contemporary lymphatic diseases * Absence of previous oncological disease in the last 5 years * Willingness to participate in the study and to provide informed consent Exclusion Criteria: * \- Previous radiotherapy treatments in the area of analysed lymph nodes * Previous chemotherapy treatments

Contact & Investigator

Central Contact

Antonia Carla Testa

✉ antoniacarla.testa@policlinicogemelli.it

📞 0630156399

Principal Investigator

Antonia Carla Testa, Professor

PRINCIPAL INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome

Frequently Asked Questions

Who can join the NCT06621823 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 99 Years, studying Lymph Node Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06621823 currently recruiting?

Yes, NCT06621823 is actively recruiting participants. Contact the research team at antoniacarla.testa@policlinicogemelli.it for enrollment information.

Where is the NCT06621823 trial being conducted?

This trial is being conducted at Roma, Italy.

Who is sponsoring the NCT06621823 clinical trial?

NCT06621823 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Antonia Carla Testa, Professor at Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology